Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

11226	Companies
248942	Keywords
176738	Articles
134747	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 12/06/2023 at 14:30, 2 years 10 months ago

Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Napo Pharmaceuticals and Advocates for Collaborative Education (ACE) have released the abstract for a quality of life survey for individuals with a cancer diagnosis, shedding light on the challenges faced. The survey findings will be presented at the December 2023 SABCS, focusing on the impacts of cancer diagnosis and treatment on quality of life, including physical and emotional well-being, treatment side effects, and the consequences of managing those side effects

Napo Pharmaceuticals Advocates For Collaborative Education Cancer Survey Quality Of Life SABCS 2023
PRESS RELEASE

published on 12/04/2023 at 14:30, 2 years 10 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) has announced the renewal of conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets) by the U.S. FDA for the treatment of chemotherapy-induced diarrhea (CID) in dogs. The renewal extends the validity until December 21, 2024, as the company plans a clinical field study to support full approval

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea
PRESS RELEASE

published on 11/30/2023 at 14:30, 2 years 10 months ago

Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
Jaguar Health, Inc. to present on Dec 5, 2023, at the MedInvest Oncology Investor Conference, discussing pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy

Crofelemer Jaguar Health Oncology Investor Conference Phase 3 Clinical Trial Cancer Therapy
PRESS RELEASE

published on 11/21/2023 at 14:30, 2 years 11 months ago

Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
PRESS RELEASE

published on 11/14/2023 at 14:00, 2 years 11 months ago

Jaguar Health Reports Third Quarter 2023 Financial Results
PRESS RELEASE

published on 11/10/2023 at 22:15, 2 years 11 months ago

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRESS RELEASE

published on 11/09/2023 at 14:30, 2 years 11 months ago

Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium
PRESS RELEASE

published on 11/08/2023 at 16:25, 2 years 11 months ago

Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
PRESS RELEASE

published on 11/08/2023 at 14:30, 2 years 11 months ago

Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
PRESS RELEASE

published on 11/07/2023 at 14:30, 2 years 11 months ago

REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST

Accesswire

Published on 10/24/2026 at 00:25, 2 days 6 hours ago

Caldwell Announces Sale of IQTalent
Published on 10/24/2026 at 00:04, 2 days 6 hours ago

Sparta Capital Ltd. Provides Corporate Update on Reinstatement Review, Financial Statement Corrections and Governance Matters
Published on 10/23/2026 at 23:30, 2 days 7 hours ago

Algo Grande Commissions Independent NI 43-101 Update to Capture First Year of Progress at Adelita
Published on 10/23/2026 at 21:55, 2 days 9 hours ago

Apex Closes Offering and Completes NASDAQ Listing
Published on 10/23/2026 at 16:00, 2 days 15 hours ago

Leggett Dynamics's Mid-Class Massage System Wins Gasgoo's Best Technical Practice Award

View all ACCESSWIRE

EQS Group

Published on 10/26/2026 at 06:45, 17 minutes ago

HBM Portfolio Company Lycia Therapeutics Raises USD 317.5 Million in Nasdaq IPO and Delivers Strong Market Debut
Published on 10/26/2026 at 06:45, 17 minutes ago

AOT Engages Over 50 Airlines and Airport at Routes World 2026 to Boost Thailand’s Global Connectivity
Published on 10/26/2026 at 02:05, 4 hours 57 minutes ago

Tin Men Capital leads US$7.4M Series A for Vision AI startup Ailytics to expand across APAC, US and Gulf
Published on 10/24/2026 at 23:44, 1 day 7 hours ago

EQS-Adhoc: HomeToGo SE: Unauthorized data exfiltration at subsidiary SECRA Bookings GmbH
Published on 10/24/2026 at 14:15, 1 day 16 hours ago

Winners of the 2026 INPD Awards Announced, C-Beauty Takes Home Multiple Prestigious Honors

Les Echos

Published on 10/23/2026 at 20:33, 2 days 10 hours ago

Disclosure of transactions in own shares from October 19 to October 23, 2026
Published on 10/23/2026 at 17:45, 2 days 13 hours ago

Imerys-10-2026-information-share-capital-and-voting-rights-as-of-30-September-2026
Published on 10/23/2026 at 07:00, 3 days ago

Safran reports third quarter 2026 revenue
Published on 10/22/2026 at 18:00, 3 days 13 hours ago

THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 3 days 13 hours ago

bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics

View all LES ECHOS COMFI WIRE